Latest Capital Management News

Vicinity Centres used its 2026 Capability Showcase to make the case for a more concentrated, premium retail portfolio, led by Chadstone and Chatswood Chase. The presentation also set out development returns, balance-sheet capacity and a sizeable residential option beside Chatswood Chase, although much of the value remains dependent on stabilisation, approvals and market conditions.

Pengana International Equities has settled Supreme Court proceedings and agreed steps aimed at ending a related Takeovers Panel application, clearing a path for its buy-back and strategic reset. Antipodes will manage the portfolio under a new Board led by interim chairman Frank Gooch after the transaction.

Viva Energy has confirmed a $2.98 Dividend Reinvestment Plan price for its 7.73-cent fully franked interim dividend. The payment is due on 30 September, with new shares issued to participating investors at a 1.5% discount.

Rivco Australia has outlined a long-term water scarcity thesis, a 61 GL portfolio concentrated in the southern Murray-Darling Basin and a revised dividend framework beginning in 2027. The ASX-listed water investor says future dividends will be anchored more heavily to operating earnings rather than realised capital gains.

Deep Yellow reported a A$13.3 million FY2026 profit and moved its Tumas uranium project closer to a targeted fourth-quarter investment decision. The company remains debt free, but acknowledges it will need external capital to fund construction.

Paragon Care has lined up an on-market buy-back of up to 82.8 million shares, worth about $10.8 million at the latest closing price, while its employee trust can acquire a further 23.9 million shares. The transactions give the healthcare group two sizeable tools for managing its capital and incentive plans, although neither maximum is guaranteed to be completed.

Raptor Metals has sold its remaining Australian Gold and Copper stake for approximately $468,200, converting a legacy asset into cash without issuing new shares. The proceeds add funding flexibility as the company advances copper exploration in New Brunswick.

Atomic Eagle’s largest shareholder has irrevocably committed to exercise 35.1 million options, giving the uranium developer a potential $10.9 million cash injection before the options expire. The company says the proceeds could fund its Zambia and Niger growth strategy through 2028 without near-term equity financing.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

Otto Energy’s attempt to sell its Gulf of America assets as a package has produced no actionable transaction, with GC 21’s decommissioning liabilities emerging as the central obstacle. The company will now pursue a separate sale of SM 71 while weighing other ways to manage GC 21.

Neurizon will redeem 1 million convertible notes held by Obsidian for US$1.15 million, while securing a two-month standstill on share sales. The biotechnology company says the transaction leaves it funded through the HEALEY ALS trial readout and completion.

Kapstream Investment Trust will begin a 12-month on-market buy-back of its fully paid ordinary units, but has not disclosed a target quantity or dollar commitment. The responsible entity can pause or end the programme without notice.